General Atomics was one of the pioneering firms in commercial nuclear energy. We continue to push the boundaries of what is possible in advanced nuclear reactors while helping to sustain our current reactor fleet and spinning off technologies that have the potential to enhance public safety and well-being.
GA's TRIGA® research reactors are the most successful reactor design in history — more than 60 have been built worldwide — and have a flawless record of inherently safe operation extending over 50-plus years. GA is building on its experience with TRIGA® in developing the next generation of advanced fission reactors. The long-term focus of the Nuclear Technologies & Materials (NTM) division is on the innovative Energy Multiplier Module (EM2™), an advanced, gas-cooled design that addresses the four core challenges facing nuclear energy – safety, waste, cost, and non-proliferation. EM2™ can be powered by spent nuclear fuel and operates up to 30 years without refueling.
To support the existing reactor fleet, GA is also leveraging EM2™ research for DOE's Accident Tolerant Fuel (ATF) program, which is developing composite cladding materials that offer a significantly higher safety margin compared to current metal alloys.
In addition, GA has developed selective gaseous extraction technology that offers a safer, more efficient method of manufacturing molybdenum-99 for nuclear medicine applications to meet growing health care imaging requirements.
GA further supports innovative energy generation through its subsidiaries, which supply uranium and other mineral products to the global nuclear industry.
Accident Tolerant Fuel
GA's revolutionary SiGA™ silicon-carbide composite is the key to an Accident Tolerant Fuel that will greatly enhance fuel rod safety and durability, and improve plant economics and performance in both current and advanced reactors.
GA has been an innovator in nuclear reactor design for its entire existence. The Energy Multiplier Module (EM2™) reactor design addresses challenges in cost, safety, nonproliferation, and waste that are critical for the future of nuclear power.
GA has developed an innovative process to extract radioisotopes for nuclear medicine more safely and effectively than previous methods.
GA's family of affiliates supplies uranium and related services to the commercial nuclear industry.